Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT00893685
Other study ID # European Commission
Secondary ID European Commiss
Status Not yet recruiting
Phase N/A
First received April 22, 2009
Last updated May 7, 2009
Start date May 2009
Est. completion date December 2011

Study information

Verified date May 2009
Source Health Information Management, Belgium
Contact Reinhard W Prior, M.D.
Phone +393341855067
Email rprior@gmail.com
Is FDA regulated No
Health authority Denmark: The Regional Committee on Biomedical Research EthicsEstonia: The State Agency of MedicineGermany: Ethics CommissionItaly: Ethics CommitteeSpain: Ethics CommitteeSweden: Regional Ethical Review Board
Study type Interventional

Clinical Trial Summary

The DREAMING clinical trial is part of the DREAMING project, which has the objective to demonstrate that the DREAMING platform consisting of integrated health monitoring, alarm handling and videoconferencing services produces clinical benefits to its users and economic benefits to the health authorities. The study evaluates the long-term (30 months) effect of continuous use of the DREAMING subsystems and is testing the hypothesis that such use is superior to usual care alone in reducing the deterioration of health related quality of life that is associated to age and chronic disease. It also tests the hypothesis that the DREAMING environment is superior to usual care in delaying the transfer to nursing or elderly homes and in reducing the incidence and duration of hospitalisation episodes. The trial will also evaluate the cost-effectiveness of the DREAMING platform. Outcomes are assessed in six different health care systems (Denmark, Estonia, Germany, Italy, Spain and Sweden) and will represent a basis for the adoption of DREAMING services by the respective health authorities.


Description:

Homes of participants are equipped with environmental sensors, motion detection, and with wireless sensors for blood pressure, blood glucose, body weight, blood oxygen saturation, peak expiratory flow and electrocardiogram. Disease related parameters are monitored at least daily and the measured values are transmitted to a central monitoring unit. In case of abnormal values, health alarms are generated and transmitted to the local health authorities to trigger eventual intervention by the physicians and nurses who normally follow the participants. Participants and health professionals can stay in contact via an easy to use, home television based videoconferencing system. Participants are also equipped with a a personal alarm and GPS-enhanced localisation system.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 300
Est. completion date December 2011
Est. primary completion date November 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 65 Years and older
Eligibility Inclusion Criteria:

Inclusion criteria:

- Diagnosis of chronic heart failure

- Diagnosis of diabetes mellitus

- Diagnosis of chronic obstructive pulmonary disease

Only in the case that the number of recruited participants is not sufficient, inclusion criteria can be extended to one or more of the following conditions:

- History of myocardial infarction

- History of stroke (brain ischemia or hemorrhage)

- History of falls within the last two years

- Hospitalization during the last two years (for every reason)

Exclusion Criteria:

- Not willing to participate (e.g non signing informed consent)

- Inability to use the DREAMING equipment

- Significant impairment of language comprehension or expression (aphasia)

- Diagnosis of dementia

- Completely dependent on others for the activities of daily living

- Living without access to ISDN or DSL service

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Device:
Wireless monitors for disease specific clinical parameters.
Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.

Locations

Country Name City State
Denmark Langeland Municipality Langeland
Estonia East Tallin Central Hospital Tallin
Germany Pflegwerk Berlin, Mediplus Berlin
Italy Azienda per i Servizi Sanitari ASS N.1 Trieste
Spain Servicio Aragones de Salud Barbastro
Sweden GP Surgery Heby

Sponsors (1)

Lead Sponsor Collaborator
Health Information Management, Belgium

Countries where clinical trial is conducted

Denmark,  Estonia,  Germany,  Italy,  Spain,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Health related quality of life as assessed by the SF-36 questionnaire, at the beginning, at midterm and at the end of the trial period 0, 15, 30 months No
Secondary Time to permanent transfer to elderly homes Measured at month 30 No
Secondary Total and average length of stay in hospital Measured at month 30 No
Secondary Number of consultations with general practitioners Measured at month 30 No
Secondary Number of consultations with medical specialists Measured at month 30 No
Secondary Number of home visits by nurses Measured at month 30 No
Secondary Number of ambulance transports Measured at month 30 No
Secondary Number of accesses to emergency rooms Measured at month 30 No
Secondary Number of falls Measured at month 30 No
Secondary Number of femur fractures Measured at month 30 No
Secondary HbA1c change over time (only for participants with a diagnosis of diabetes) Measured at month 30 No
Secondary Survival Measured at month 30 No
Secondary Depression as measured by HADS Measured at months 0, 15 and 30 No
Secondary Number of hospitalisations Measured at month 30 No
Secondary Number of permanent transfers to elderly homes Measured at month 30 No
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A